DISCLOSURES: Nur: Novartis Pharmaceuticals: Consultancy. Maertens:Cidara: Other: Personal fees and non-financial support; Gilead Sciences: Other: Grants, personal fees and non-financial support; Amplyx: Other: Personal fees and non-financial support; Merck: Other: Personal fees and non-financial support; Pfizer: Other: Grant and personal fees; Astellas Pharma: Other: Personal fees and non-financial support; F2G: Other: Personal fees and non-financial support. Deeren:Alexion, Amgen, Janssen, Roche, Sunesis, Takeda, Sanofi: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding.

Additional Metadata
Persistent URL dx.doi.org/10.1182/blood-2019-124659, hdl.handle.net/1765/121593
Journal Blood
Rights no subscription
Citation
De Jong, C.N. (Cornelis N.), Meijer, E, Bakunina, K. (Katerina), Nur, E, van Marwijk Kooij, M. (Marinus), de Groot, M, … Broers, A.E.C. (2019). Post-Transplantation Cyclophosphamide after Allogeneic Hematopoietic Stem Cell Transplantation: Results of the Prospective Randomized HOVON-96 Trial in Recipients of Matched Related and Unrelated Donors. Blood, 134(1). doi:10.1182/blood-2019-124659